
    
      A phase I/II study of the efficacy of CPX-351 treatment in patients with higher risk
      myelodysplastic syndromes : as first line treatment or after hypomethylating agents failure.

      CPX-351 is an advanced liposomal formulation of daunorubicin and cytarabine encapsulated at a
      1:5 ratio.

      Patients will receive induction treatment with CPX-351. Patients in response (complete
      response (CR), complete response with incomplete hematologic improvement (CRi), partial
      response (PR)) after induction will receive monthly courses of consolidation therapy with
      CPX-351.
    
  